Dr Lauran Vogelaar and colleagues from the Netherlands assessed the effectiveness of solution-focused therapy (SFT) on fatigue and quality of life (QoL) in patients with fatigued inflammatory bowel disease (IBD).
The research team performed a randomized controlled trial in 2 Dutch hospitals.
Patients with IBD with quiescent IBD and with a Checklist Individual Strength—Fatigue (CIS—fatigue) score of ≥35 were enrolled.
Patients were 1:1 randomized to receive solution-focused therapy in Group 1 or care as usual in Group 2 for 3 months.
The team followed patients for a further 6 months after the solution-focused therapy.
|39% of patients in Group 1 had a CIS-fatigue score below 35|
Primary endpoint was defined as changes in fatigue and QoL during follow-up.
The team's secondary endpoints included change in anxiety and depression, medication use, side effects to medication, disease activity, laboratory parameters, and sleep quality.
The team evaluated 98 patients, of whom 63% were women, with a mean age of 40 years.
After the solution-focused therapy course, 39% of patients in Group 1 had a CIS-fatigue score below 35 compared with 18% of patients in Group 2.
The researchers found that Group 1 also showed a greater reduction in fatigue across the first 6 months compared with Group 2.
The team noted that patients in Group 1 had a significant higher mean IBD questionnaire change at 3 months.
At 9 months, no significant differences between the 2 groups were observed.
Dr Vogelaar's team concludes, "Solution-focused therapy has a significant beneficial effect on the severity of fatigue and QoL in patients with quiescent IBD."
"However, this effect diminished during follow-up."